Strs Ohio Reduces Stock Holdings in Gilead Sciences, Inc. $GILD

Key Points

• STRS Ohio trimmed its stake in Gilead Sciences by 3.1%, selling 17,368 shares and now holds 541,219 shares valued at approximately $66.43 million.
• Significant insider selling occurred recently: CEO Daniel O'Day sold 115,640 shares (~$17.35M) and the CFO sold 3,000 shares, with insiders offloading 178,640 shares (~$26.58M) over the past three months and now owning just 0.30% of the stock.
• Positive company catalysts include an FDA priority review for Gilead’s once‑daily bictegravir+lenacapavir HIV regimen and completion of the ~$7.8 billion Arcellx acquisition, while analysts have raised targets and the consensus rating is a Moderate Buy with a $157.35 target.

Strs Ohio decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 541,219 shares of the biopharmaceutical company's stock after selling 17,368 shares during the period. Strs Ohio's holdings in Gilead Sciences were worth $66,429,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Corundum Trust Company INC bought a new stake in Gilead Sciences during the 3rd quarter valued at $26,000. Ares Financial Consulting LLC bought a new stake in Gilead Sciences during the 4th quarter valued at $28,000. Financial Consulate Inc. raised its holdings in Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 109 shares during the period. North Star Investment Management Corp. raised its holdings in Gilead Sciences by 54.8% during the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 86 shares during the period. Finally, MTM Investment Management LLC raised its holdings in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 176 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: FDA gives priority review to Gilead’s once‑daily bictegravir + lenacapavir HIV regimen, shortening the path to U.S. commercialization if approved — a clear revenue and de‑risking catalyst. Read More.
• Positive Sentiment: Gilead completed the Arcellx acquisition (~$7.8B), adding the anito‑cel cell therapy to its oncology pipeline and boosting longer‑term growth optionality beyond antivirals. Read More.
• Positive Sentiment: Analyst bullishness: Morgan Stanley and other shops have raised price targets/ratings recently, signaling analyst support that can attract buyers. Read More.
• Neutral Sentiment: Gilead scheduled presentations at several investor conferences (BofA, RBC, Bernstein, Goldman Sachs) — increases visibility and provides opportunities to update guidance/portfolio progress but is informational rather than a direct catalyst. Read More.
• Neutral Sentiment: Pre‑earnings coverage highlights HIV franchise strength versus cell‑therapy cost/headwinds; Wall Street expects modest earnings growth into the next print — sets expectations for the upcoming report. Read More.
• Negative Sentiment: CEO Daniel O’Day sold shares under a Rule 10b5‑1 plan (recent transactions disclosed), which can create short‑term headline pressure even if planned. Read More.
• Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking more transparency on patent exclusivities — raises governance/IP scrutiny that could produce regulatory or PR noise around future exclusivity‑dependent revenues. Read More.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the transaction, the chief financial officer directly owned 176,191 shares of the company's stock, valued at approximately $24,835,883.36. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 115,640 shares of the firm's stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the transaction, the chief executive officer directly owned 613,912 shares in the company, valued at $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 178,640 shares of company stock valued at $26,584,250. 0.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on GILD shares. Scotiabank boosted their target price on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a "sector outperform" rating in a report on Wednesday, February 11th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an "overweight" rating in a report on Wednesday, February 11th. Jefferies Financial Group initiated coverage on shares of Gilead Sciences in a report on Tuesday, March 10th. They set a "buy" rating and a $180.00 target price on the stock. Oppenheimer upped their price target on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an "outperform" rating in a report on Wednesday, February 11th. Finally, Wolfe Research upped their price target on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an "outperform" rating in a report on Thursday, February 12th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $157.35.

Gilead Sciences Stock Up 0.6%

GILD opened at $131.65 on Friday. The stock has a market cap of $163.41 billion, a PE ratio of 19.45, a P/E/G ratio of 1.73 and a beta of 0.39. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 52 week low of $95.29 and a 52 week high of $157.29. The business's fifty day simple moving average is $140.49 and its 200 day simple moving average is $132.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same period in the prior year, the business posted $1.90 earnings per share. The company's revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 8.62 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. Gilead Sciences's payout ratio is 48.45%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.